Defining the Emergence of New Immunotherapy Approaches in Breast Cancer: Role of Myeloid-Derived Suppressor Cells

Breast cancer (BC) continues to be the most diagnosed tumor in women and a very heterogeneous disease both inter- and intratumoral, mainly given by the variety of molecular profiles with different biological and clinical characteristics. Despite the advancements in early detection and therapeutic strategies, the survival rate is low in patients who develop metastatic disease. Therefore, it is mandatory to explore new approaches to achieve better responses. In this regard, immunotherapy arose as a promising alternative to conventional treatments due to its ability to modulate the immune system, which may play a dual role in this disease since the relationship between the immune system and BC cells depends on several factors: the tumor histology and size, as well as the involvement of lymph nodes, immune cells, and molecules that are part of the tumor microenvironment. Particularly, myeloid-derived suppressor cell (MDSC) expansion is one of the major immunosuppressive mechanisms used by breast tumors since it has been associated with worse clinical stage, metastatic burden, and poor efficacy of immunotherapies. This review focuses on the new immunotherapies in BC in the last five years. Additionally, the role of MDSC as a therapeutic target in breast cancer will be described.

[1]  F. Rojo,et al.  Pembrolizumab in combination with gemcitabine for patients with HER2-negative advanced breast cancer: GEICAM/2015–04 (PANGEA-Breast) study , 2022, BMC Cancer.

[2]  Yi Wang,et al.  Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy , 2022, Journal of Hematology & Oncology.

[3]  A. Díez-Pascual,et al.  Breast cancer vaccines: New insights into immunomodulatory and nano-therapeutic approaches. , 2022, Journal of controlled release : official journal of the Controlled Release Society.

[4]  Frederick M. Howard,et al.  Clinical trials of immunotherapy in triple-negative breast cancer , 2022, Breast Cancer Research and Treatment.

[5]  Baorui Liu,et al.  Recent Progress on Therapeutic Vaccines for Breast Cancer , 2022, Frontiers in Oncology.

[6]  A. Cusmai,et al.  KEYNOTE-522, IMpassion031 and GeparNUEVO: changing the paradigm of neoadjuvant immune checkpoint inhibitors in early triple-negative breast cancer. , 2022, Future oncology.

[7]  U. Ray,et al.  Exploiting LRRC15 as a Novel Therapeutic Target in Cancer , 2022, Cancer research.

[8]  P. Ferrari,et al.  Molecular Mechanisms, Biomarkers and Emerging Therapies for Chemotherapy Resistant TNBC , 2022, International journal of molecular sciences.

[9]  Keda Yu,et al.  Breast Cancer Vaccines: Disappointing or Promising? , 2022, Frontiers in Immunology.

[10]  Y. Geng,et al.  CDK4 and CDK6 kinases: From basic science to cancer therapy , 2022, Science.

[11]  A. Badowska-Kozakiewicz,et al.  Current State of Knowledge on the Immune Checkpoint Inhibitors in Triple-Negative Breast Cancer Treatment: Approaches, Efficacy, and Challenges , 2022, Clinical Medicine Insights. Oncology.

[12]  W. Gradishar,et al.  Role of Fcγ receptors in HER2-targeted breast cancer therapy , 2022, Journal for ImmunoTherapy of Cancer.

[13]  Lixi Li,et al.  Antibody-drug conjugates in HER2-positive breast cancer , 2021, Chinese medical journal.

[14]  Yeon-Hee Park,et al.  Trastuzumab deruxtecan for HER2+ advanced breast cancer. , 2021, Future oncology.

[15]  Fengqian Chen,et al.  Targeting Innate Immunity in Breast Cancer Therapy: A Narrative Review , 2021, Frontiers in Immunology.

[16]  A. Rotili,et al.  Breast Cancer Surgery: New Issues , 2021, Current oncology.

[17]  Frederick M. Howard,et al.  The emerging role of immune checkpoint inhibitors for the treatment of breast cancer , 2021, Expert opinion on investigational drugs.

[18]  Yuhua Li,et al.  Application of HER2 peptide vaccines in patients with breast cancer: a systematic review and meta-analysis , 2021, Cancer cell international.

[19]  M. Rizzo,et al.  Targeting ADCC: A different approach to HER2 breast cancer in the immunotherapy era , 2021, Breast.

[20]  P. Neven,et al.  Sacituzumab govitecan and trastuzumab deruxtecan: two new antibody–drug conjugates in the breast cancer treatment landscape , 2021, ESMO open.

[21]  R. Naidu,et al.  Curcumin: Modulator of Key Molecular Signaling Pathways in Hormone-Independent Breast Cancer , 2021, Cancers.

[22]  R. Bartsch SABCS 2020: update on triple-negative and metastatic HER2-positive breast cancer , 2021, memo - Magazine of European Medical Oncology.

[23]  A. Bardia,et al.  Sacituzumab Govitecan For Metastatic Triple Negative Breast Cancer: Clinical Overview And Management Of Potential Toxicities. , 2021, The oncologist.

[24]  Z. Gatalica,et al.  Trop-2 protein as a therapeutic target: A focused review on Trop-2-based antibody-drug conjugates and their predictive biomarkers , 2021, Bosnian journal of basic medical sciences.

[25]  M. Lejeune,et al.  Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial , 2021, Journal for ImmunoTherapy of Cancer.

[26]  A. Tan,et al.  Checkpoint inhibitor therapy for metastatic triple-negative breast cancer , 2021, Cancer and Metastasis Reviews.

[27]  K. Blackwell,et al.  Glembatumumab vedotin for patients with metastatic, gpNMB overexpressing, triple-negative breast cancer (“METRIC”): a randomized multicenter study , 2021, NPJ breast cancer.

[28]  Min Li,et al.  Evaluation of BRCA1 and BRCA2 as Indicators of Response to Immune Checkpoint Inhibitors , 2021, JAMA network open.

[29]  F. Grossi,et al.  Trastuzumab Deruxtecan: Changing the Destiny of HER2 Expressing Solid Tumors , 2021, International journal of molecular sciences.

[30]  G. Demetri,et al.  First-in-Human Phase I Study of ABBV-085, an Antibody–Drug Conjugate Targeting LRRC15, in Sarcomas and Other Advanced Solid Tumors , 2021, Clinical Cancer Research.

[31]  A. Turnbull,et al.  Current trends in the treatment of HR+/HER2+ breast cancer. , 2021, Future oncology.

[32]  C. Brito,et al.  The Peripheral Immune Landscape of Breast Cancer: Clinical Findings and In Vitro Models for Biomarker Discovery , 2021, Cancers.

[33]  R. Barroso-Sousa,et al.  Clinical Development of New Antibody–Drug Conjugates in Breast Cancer: To Infinity and Beyond , 2021, BioDrugs.

[34]  F. Rojo,et al.  Circulating immune biomarkers in peripheral blood correlate with clinical outcomes in advanced breast cancer , 2021, Scientific Reports.

[35]  J. Goo,et al.  Feasibility of implementing a national lung cancer screening program: Interim results from the Korean Lung Cancer Screening Project (K-LUCAS) , 2021, Translational lung cancer research.

[36]  P. Fasching,et al.  Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer , 2021, JAMA oncology.

[37]  M. Zubair,et al.  Advanced Approaches to Breast Cancer Classification and Diagnosis , 2021, Frontiers in Pharmacology.

[38]  Ghaneya Al-Khadairi,et al.  Immune Checkpoint Inhibitors in Triple Negative Breast Cancer Treatment: Promising Future Prospects , 2021, Frontiers in Oncology.

[39]  M. Dieci,et al.  An overview of immune checkpoint inhibitors in breast cancer , 2020, Exploration of Targeted Anti-tumor Therapy.

[40]  J. Wippermann,et al.  Delicate Role of PD-L1/PD-1 Axis in Blood Vessel Inflammatory Diseases: Current Insight and Future Significance , 2020, International journal of molecular sciences.

[41]  D. Kwapisz Pembrolizumab and atezolizumab in triple-negative breast cancer , 2020, Cancer Immunology, Immunotherapy.

[42]  S. Gulati,et al.  Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study. , 2020, The Lancet. Oncology.

[43]  A. Ianaro,et al.  The New Era of Cancer Immunotherapy: Targeting Myeloid-Derived Suppressor Cells to Overcome Immune Evasion , 2020, Frontiers in Immunology.

[44]  J. Abraham,et al.  Novel HER2–targeted therapies for HER2–positive metastatic breast cancer , 2020, Cancer.

[45]  J. Koo,et al.  Role of Tumor-Associated Myeloid Cells in Breast Cancer , 2020, Cells.

[46]  A. Hartmann,et al.  Histology of Luminal Breast Cancer , 2020, Breast Care.

[47]  J. Szumiło,et al.  Correction to: Accumulation of blood-circulating PD-L1-expressing M-MDSCs and monocytes/macrophages in pretreatment ovarian cancer patients is associated with soluble PD-L1 , 2020, Journal of Translational Medicine.

[48]  Z. Gatalica,et al.  Targeting HER2 expression in cancer: New drugs and new indications , 2020, Bosnian journal of basic medical sciences.

[49]  Ming-Hai Wang,et al.  Antibody-drug conjugates targeting RON receptor tyrosine kinase as a novel strategy for treatment of triple-negative breast cancer. , 2020, Drug discovery today.

[50]  L. Fu,et al.  PD-1/PD-L1 Based Combinational Cancer Therapy: Icing on the Cake , 2020, Frontiers in Pharmacology.

[51]  Tianhao Weng,et al.  RON and MET Co-overexpression Are Significant Pathological Characteristics of Poor Survival and Therapeutic Targets of Tyrosine Kinase Inhibitors in Triple-Negative Breast Cancer , 2020, Cancer research and treatment : official journal of Korean Cancer Association.

[52]  M. Mercogliano,et al.  Tumor Necrosis Factor α Blockade: An Opportunity to Tackle Breast Cancer , 2020, Frontiers in Oncology.

[53]  P. De,et al.  The trastuzumab era: current and upcoming targeted HER2+ breast cancer therapies. , 2020, American journal of cancer research.

[54]  Z. Shao,et al.  Molecular subtypes and precision treatment of triple-negative breast cancer , 2020, Annals of translational medicine.

[55]  K. Leandersson,et al.  The Generation and Identity of Human Myeloid-Derived Suppressor Cells , 2020, Frontiers in Oncology.

[56]  J. Behravan,et al.  HER2-Positive Breast Cancer Immunotherapy: A Focus on Vaccine Development , 2020, Archivum Immunologiae et Therapiae Experimentalis.

[57]  C. Sotiriou,et al.  Mechanisms of resistance to trastuzumab emtansine (T-DM1) in HER2-positive breast cancer , 2019, British Journal of Cancer.

[58]  G. Lippi,et al.  Current Cancer Epidemiology , 2019, Journal of epidemiology and global health.

[59]  C. Solinas,et al.  Breast cancer vaccines: Heeding the lessons of the past to guide a path forward. , 2019, Cancer treatment reviews.

[60]  R. Zagożdżon,et al.  Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer , 2019, Cancers.

[61]  F. Fisusi,et al.  Drug Combinations in Breast Cancer Therapy , 2019, Pharmaceutical nanotechnology.

[62]  A. Tan,et al.  Open-Label Clinical Trial of Niraparib Combined With Pembrolizumab for Treatment of Advanced or Metastatic Triple-Negative Breast Cancer. , 2019, JAMA oncology.

[63]  J. Soria,et al.  Beyond DNA repair: the novel immunological potential of PARP inhibitors , 2019, Molecular & cellular oncology.

[64]  C. Brennan,et al.  Tumor mutational load predicts survival after immunotherapy across multiple cancer types , 2019, Nature Genetics.

[65]  P. Duijf,et al.  Circulating myeloid‐derived suppressor cells: An independent prognostic factor in patients with breast cancer , 2018, Journal of cellular physiology.

[66]  J. Behravan,et al.  Towards Breast Cancer Vaccines, Progress and Challenges. , 2019, Current drug discovery technologies.

[67]  Tianhao Weng,et al.  RON Receptor Tyrosine Kinase as a Therapeutic Target for Eradication of Triple-Negative Breast Cancer: Efficacy of Anti-RON ADC Zt/g4-MMAE , 2018, Molecular Cancer Therapeutics.

[68]  S. H. van der Burg Correlates of immune and clinical activity of novel cancer vaccines. , 2018, Seminars in immunology.

[69]  Timothy A. Chan,et al.  The hallmarks of successful anticancer immunotherapy , 2018, Science Translational Medicine.

[70]  A. Jemal,et al.  Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries , 2018, CA: a cancer journal for clinicians.

[71]  Lucy M. De La Cruz,et al.  Immunotherapy for Breast Cancer is Finally at the Doorstep: Immunotherapy in Breast Cancer , 2018, Annals of Surgical Oncology.

[72]  K. Gish,et al.  LRRC15 Is a Novel Mesenchymal Protein and Stromal Target for Antibody-Drug Conjugates. , 2018, Cancer research.

[73]  Chau Dang,et al.  Overview of Breast Cancer Therapy. , 2018, PET clinics.

[74]  V. Sánchez-Margalet,et al.  New horizons in breast cancer: the promise of immunotherapy , 2018, Clinical and Translational Oncology.

[75]  I. Makhoul,et al.  Breast Cancer Immunotherapy: An Update , 2018, Breast cancer : basic and clinical research.

[76]  S. Edge,et al.  New and Important Changes in the TNM Staging System for Breast Cancer. , 2018, American Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual Meeting.

[77]  Jack Junjie Chan,et al.  What is the role of immunotherapy in breast cancer? , 2018, Chinese clinical oncology.

[78]  C. Sohn,et al.  Immunooncology in Breast Cancer: Active and Passive Vaccination Strategies , 2018, Breast Care.

[79]  C. Fenselau,et al.  Myeloid-Derived Suppressor Cells: Immune-Suppressive Cells That Impair Antitumor Immunity and Are Sculpted by Their Environment , 2018, The Journal of Immunology.

[80]  S. Sleijfer,et al.  Breast cancer genomics and immuno-oncological markers to guide immune therapies. , 2017, Seminars in cancer biology.

[81]  J. Jeruss,et al.  Molecular Subtypes and Local-Regional Control of Breast Cancer. , 2018, Surgical oncology clinics of North America.

[82]  B. Czerniecki,et al.  The clinical development of vaccines for HER2+ breast cancer: Current landscape and future perspectives. , 2017, Cancer treatment reviews.

[83]  A. Kitano,et al.  Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody-drug conjugate, in patients with advanced breast and gastric or gastro-oesophageal tumours: a phase 1 dose-escalation study. , 2017, The Lancet. Oncology.

[84]  Xiaosheng Wang,et al.  A Comprehensive Immunologic Portrait of Triple-Negative Breast Cancer , 2017, bioRxiv.

[85]  M. Akram,et al.  Awareness and current knowledge of breast cancer , 2017, Biological Research.

[86]  A. Børresen-Dale,et al.  Breast Cancer Molecular Stratification: From Intrinsic Subtypes to Integrative Clusters. , 2017, The American journal of pathology.

[87]  T. Sørlie,et al.  Immune Escape in Breast Cancer During In Situ to Invasive Carcinoma Transition. , 2017, Cancer discovery.

[88]  N. Harada,et al.  Mode of action of pertuzumab in combination with trastuzumab plus docetaxel therapy in a HER2-positive breast cancer xenograft model , 2017, Oncology letters.

[89]  N. Othman,et al.  Curcumin: the spicy modulator of breast carcinogenesis , 2017, Journal of experimental & clinical cancer research : CR.

[90]  C. Perou,et al.  Combined immune checkpoint blockade as a therapeutic strategy for BRCA1-mutated breast cancer , 2017, Science Translational Medicine.

[91]  C. Perou,et al.  Intrinsic Subtypes and Gene Expression Profiles in Primary and Metastatic Breast Cancer. , 2017, Cancer research.

[92]  A. Kitano,et al.  Tumour-infiltrating lymphocytes are correlated with higher expression levels of PD-1 and PD-L1 in early breast cancer , 2017, ESMO Open.

[93]  C. Heldin,et al.  The transcription factor MAFK induces EMT and malignant progression of triple-negative breast cancer cells through its target GPNMB , 2017, Science Signaling.

[94]  G. Giaccone,et al.  First-in-human phase 1 study of margetuximab (MGAH22), an Fc-modified chimeric monoclonal antibody, in patients with HER2-positive advanced solid tumors , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[95]  D. Gabrilovich Myeloid-Derived Suppressor Cells , 2017, Cancer Immunology Research.

[96]  K. Leandersson,et al.  On the origin of myeloid-derived suppressor cells , 2016, Oncotarget.

[97]  Masato Takahashi,et al.  The therapeutic candidate for immune checkpoint inhibitors elucidated by the status of tumor-infiltrating lymphocytes (TILs) and programmed death ligand 1 (PD-L1) expression in triple negative breast cancer (TNBC) , 2017, Breast Cancer.

[98]  C. Sotiriou,et al.  Relevance of Tumor-Infiltrating Immune Cell Composition and Functionality for Disease Outcome in Breast Cancer , 2017, Journal of the National Cancer Institute.

[99]  F. Rojo,et al.  Breast Cancer Immunology and Immunotherapy: Current Status and Future Perspectives. , 2017, International review of cell and molecular biology.

[100]  G. Plitas,et al.  Regulatory T Cells Exhibit Distinct Features in Human Breast Cancer. , 2016, Immunity.

[101]  J. Balko,et al.  Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease , 2016, Nature Reviews Clinical Oncology.

[102]  Qiming Sun,et al.  Suppressive role of myeloid-derived suppressor cells (MDSCs) in the microenvironment of breast cancer and targeted immunotherapies , 2016, Oncotarget.

[103]  Peter J. Murray,et al.  Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards , 2016, Nature Communications.

[104]  J. Murray,et al.  Primary analysis of a prospective, randomized, single-blinded phase II trial evaluating the HER2 peptide AE37 vaccine in breast cancer patients to prevent recurrence. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[105]  Peter A. Fasching,et al.  Tumor-Infiltrating Lymphocytes: A Predictive and Prognostic Biomarker in Neoadjuvant-Treated HER2-Positive Breast Cancer , 2016, Clinical Cancer Research.

[106]  E. Shahverdi,et al.  A Review of the Clinical Implications of Breast Cancer Biology , 2016, Electronic physician.

[107]  F. Marincola,et al.  Immunogenic Subtypes of Breast Cancer Delineated by Gene Classifiers of Immune Responsiveness , 2016, Cancer Immunology Research.

[108]  A. Nottegar,et al.  Predictive and Prognostic Role of Tumor-Infiltrating Lymphocytes for Early Breast Cancer According to Disease Subtypes: Sensitivity Analysis of Randomized Trials in Adjuvant and Neoadjuvant Setting. , 2016, The oncologist.

[109]  A. Callegaro,et al.  A phase I/II trial of the safety and clinical activity of a HER2-protein based immunotherapeutic for treating women with HER2-positive metastatic breast cancer , 2016, Breast Cancer Research and Treatment.

[110]  W. Gillanders,et al.  Mammaglobin-A is a target for breast cancer vaccination , 2016, Oncoimmunology.

[111]  Alan Ashworth,et al.  BRCAness revisited , 2016, Nature Reviews Cancer.

[112]  A. Arance,et al.  Clinical implications of the intrinsic molecular subtypes of breast cancer. , 2015, Breast.

[113]  S. Saussez,et al.  Macrophage migration inhibitory factor involvement in breast cancer (Review) , 2015, International journal of oncology.

[114]  A. Tzankov,et al.  Role of the Tumor Microenvironment in Breast Cancer , 2015, Pathobiology.

[115]  Helena Jernström,et al.  Systemic Monocytic-MDSCs Are Generated from Monocytes and Correlate with Disease Progression in Breast Cancer Patients , 2015, PloS one.

[116]  P. Sharma,et al.  Immune Checkpoint Targeting in Cancer Therapy: Toward Combination Strategies with Curative Potential , 2015, Cell.

[117]  N. Mount,et al.  Genetically modified T cells in cancer therapy: opportunities and challenges , 2015, Disease Models & Mechanisms.

[118]  T. Nielsen,et al.  The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[119]  A. Nesterova,et al.  SGN–LIV1A: A Novel Antibody–Drug Conjugate Targeting LIV-1 for the Treatment of Metastatic Breast Cancer , 2014, Molecular Cancer Therapeutics.

[120]  Robin L. Anderson,et al.  BMP4 inhibits breast cancer metastasis by blocking myeloid-derived suppressor cell activity. , 2014, Cancer research.

[121]  I. Melero,et al.  Therapeutic vaccines for cancer: an overview of clinical trials , 2014, Nature Reviews Clinical Oncology.

[122]  E. Mittendorf,et al.  The HER2 peptide nelipepimut-S (E75) vaccine (NeuVax™) in breast cancer patients at risk for recurrence: correlation of immunologic data with clinical response. , 2014, Immunotherapy.

[123]  Deepak Mittal,et al.  New insights into cancer immunoediting and its three component phases--elimination, equilibrium and escape. , 2014, Current opinion in immunology.

[124]  P. Coulie,et al.  Tumour antigens recognized by T lymphocytes: at the core of cancer immunotherapy , 2014, Nature Reviews Cancer.

[125]  M. Khorramizadeh,et al.  Silibinin inhibits accumulation of myeloid-derived suppressor cells and tumor growth of murine breast cancer , 2014, Cancer medicine.

[126]  N. Ibrahim,et al.  Survival Advantage in Patients with Metastatic Breast Cancer Receiving Endocrine Therapy plus Sialyl Tn-KLH Vaccine: Post Hoc Analysis of a Large Randomized Trial , 2013, Journal of Cancer.

[127]  N. Sardesai,et al.  Highly Optimized DNA Vaccine Targeting Human Telomerase Reverse Transcriptase Stimulates Potent Antitumor Immunity , 2013, Cancer Immunology Research.

[128]  J. Markowitz,et al.  Myeloid-derived suppressor cells in breast cancer , 2013, Breast Cancer Research and Treatment.

[129]  V. Sánchez-Margalet,et al.  New Insights into the Role of the Immune Microenvironment in Breast Carcinoma , 2013, Clinical & developmental immunology.

[130]  M. Einstein,et al.  Myeloid-derived suppressor cells have a central role in attenuated Listeria monocytogenes-based immunotherapy against metastatic breast cancer in young and old mice , 2013, British Journal of Cancer.

[131]  C. Liu,et al.  Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion , 2013, Nature Medicine.

[132]  D. Templeton,et al.  Macrophage Migration Inhibitory Factor Promotes Tumor Growth and Metastasis by Inducing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment , 2012, The Journal of Immunology.

[133]  J. Blay,et al.  Impaired IFN-α production by plasmacytoid dendritic cells favors regulatory T-cell expansion that may contribute to breast cancer progression. , 2012, Cancer research.

[134]  Jean-Pierre Abastado,et al.  Immune Microenvironment in Tumor Progression: Characteristics and Challenges for Therapy , 2012, Journal of oncology.

[135]  F. Claret,et al.  Trastuzumab: Updated Mechanisms of Action and Resistance in Breast Cancer , 2012, Front. Oncol..

[136]  Mark J. Smyth,et al.  Cancer immunoediting by the innate immune system in the absence of adaptive immunity , 2012, The Journal of experimental medicine.

[137]  F. Sarkar,et al.  A Th1 cytokine–enriched microenvironment enhances tumor killing by activated T cells armed with bispecific antibodies and inhibits the development of myeloid-derived suppressor cells , 2012, Cancer Immunology, Immunotherapy.

[138]  K. Blackwell,et al.  Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion , 2012, Journal of Translational Medicine.

[139]  P. Moore,et al.  Anti-tumor activity and toxicokinetics analysis of MGAH22, an anti-HER2 monoclonal antibody with enhanced Fcγ receptor binding properties , 2011, Breast Cancer Research.

[140]  Timothy C Wang,et al.  Curcumin Induces the Differentiation of Myeloid-Derived Suppressor Cells and Inhibits Their Interaction with Cancer Cells and Related Tumor Growth , 2011, Cancer Prevention Research.

[141]  A. Tres,et al.  Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. , 2011, The oncologist.

[142]  Lisa L. Smith,et al.  Activated NKT Cells and NK Cells Render T Cells Resistant to Myeloid-Derived Suppressor Cells and Result in an Effective Adoptive Cellular Therapy against Breast Cancer in the FVBN202 Transgenic Mouse , 2011, The Journal of Immunology.

[143]  X. Chen,et al.  Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. , 2011, The Journal of clinical investigation.

[144]  S. Quezada,et al.  Shifting the equilibrium in cancer immunoediting: from tumor tolerance to eradication , 2011, Immunological reviews.

[145]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[146]  J. Bergh,et al.  Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial , 2010, Journal of Translational Medicine.

[147]  L. Coussens,et al.  Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity , 2010, Cancer and Metastasis Reviews.

[148]  Jeffrey W. Pollard,et al.  Macrophage Diversity Enhances Tumor Progression and Metastasis , 2010, Cell.

[149]  M. Hallett,et al.  Glycoprotein Nonmetastatic B Is an Independent Prognostic Indicator of Recurrence and a Novel Therapeutic Target in Breast Cancer , 2010, Clinical Cancer Research.

[150]  J. Zimmer,et al.  Cytokine Levels Correlate with Immune Cell Infiltration after Anti-VEGF Therapy in Preclinical Mouse Models of Breast Cancer , 2009, PloS one.

[151]  James A. Williams,et al.  Plasmid DNA vaccine vector design: impact on efficacy, safety and upstream production. , 2009, Biotechnology advances.

[152]  Alberto Mantovani,et al.  Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability. , 2009, Carcinogenesis.

[153]  P. Sinha,et al.  Myeloid-Derived Suppressor Cells: Linking Inflammation and Cancer 1 , 2009, The Journal of Immunology.

[154]  Srinivas Nagaraj,et al.  Myeloid-derived suppressor cells as regulators of the immune system , 2009, Nature Reviews Immunology.

[155]  K. Anderson Tumor Vaccines for Breast Cancer , 2009, Cancer investigation.

[156]  F. Pépin,et al.  Osteoactivin Promotes Breast Cancer Metastasis to Bone , 2007, Molecular Cancer Research.

[157]  A. Sica,et al.  Altered macrophage differentiation and immune dysfunction in tumor development. , 2007, The Journal of clinical investigation.

[158]  E. Mittendorf,et al.  Evaluation of the HER2/neu‐derived peptide GP2 for use in a peptide‐based breast cancer vaccine trial , 2006, Cancer.

[159]  A. Berns,et al.  Immunogenicity, including vitiligo, and feasibility of vaccination with autologous GM-CSF-transduced tumor cells in metastatic melanoma patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[160]  C. Shriver,et al.  Clinical trial results of a HER2/neu (E75) vaccine to prevent recurrence in high-risk breast cancer patients. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[161]  J. Berzofsky,et al.  Vaccination by Genetically Modified Dendritic Cells Expressing a Truncated neu Oncogene Prevents Development of Breast Cancer in Transgenic Mice , 2004, Cancer Research.

[162]  R. Schreiber,et al.  The immunobiology of cancer immunosurveillance and immunoediting. , 2004, Immunity.

[163]  M. Atkins,et al.  Fusion Cell Vaccination of Patients with Metastatic Breast and Renal Cancer Induces Immunological and Clinical Responses , 2004, Clinical Cancer Research.

[164]  M. Cheever,et al.  Effect of dose on immune response in patients vaccinated with an her-2/neu intracellular domain protein--based vaccine. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[165]  S. Henrickson,et al.  T-cell priming by dendritic cells in lymph nodes occurs in three distinct phases , 2004, Nature.

[166]  G. Hortobagyi,et al.  Toxicity, immunogenicity, and induction of E75-specific tumor-lytic CTLs by HER-2 peptide E75 (369-377) combined with granulocyte macrophage colony-stimulating factor in HLA-A2+ patients with metastatic breast and ovarian cancer. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[167]  T. Foy,et al.  Designing HER2 vaccines. , 2002, Seminars in oncology.

[168]  C. J. Clements,et al.  The global impact of vaccines containing aluminium adjuvants. , 2002, Vaccine.

[169]  R. Elliott,et al.  Vaccination with a mixed vaccine of autogenous and allogeneic breast cancer cells and tumor associated antigens CA15-3, CEA and CA125--results in immune and clinical responses in breast cancer patients. , 2000, Cancer biotherapy & radiopharmaceuticals.

[170]  E. von Hofe,et al.  Increasing the potency of MHC class II-presented epitopes by linkage to Ii-Key peptide. , 2000, Vaccine.

[171]  A. Gross,et al.  Regression of human metastatic renal cell carcinoma after vaccination with tumor cell–dendritic cell hybrids , 2000, Nature Medicine.

[172]  H. Rammensee,et al.  Her-2/neu-derived peptides are tumor-associated antigens expressed by human renal cell and colon carcinoma lines and are recognized by in vitro induced specific cytotoxic T lymphocytes. , 1998, Cancer research.

[173]  M. Bass,et al.  Human telomerase contains evolutionarily conserved catalytic and structural subunits. , 1997, Genes & development.

[174]  F. Marshall,et al.  Bioactivity of autologous irradiated renal cell carcinoma vaccines generated by ex vivo granulocyte-macrophage colony-stimulating factor gene transfer. , 1997, Cancer research.

[175]  W. Sauerbrei,et al.  Tumor-Cell Number and Viability as Quality and Efficacy Parameters of Autologous Virus-Modified Cancer Vaccines in Patients With Breast or Ovarian Cancer , 1997 .

[176]  D. Laface,et al.  Identification of Her-2/Neu CTL epitopes using double transgenic mice expressing HLA-A2.1 and human CD.8. , 1997, Human immunology.

[177]  J. Murray,et al.  Identification of naturally processed human ovarian peptides recognized by tumor-associated CD8+ cytotoxic T lymphocytes. , 1997, Cancer research.

[178]  J. Taylor‐Papadimitriou,et al.  A randomised phase II study of sialyl-Tn and DETOX-B adjuvant with or without cyclophosphamide pretreatment for the active specific immunotherapy of breast cancer. , 1996, British Journal of Cancer.

[179]  F. Oesch,et al.  Granulocyte‐macrophage‐colony‐stimulating factor enhances immune responses to melanoma‐associated peptides in vivo , 1996, International journal of cancer.

[180]  J. Wharton,et al.  Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines , 1995, The Journal of experimental medicine.

[181]  C B Harley,et al.  Specific association of human telomerase activity with immortal cells and cancer. , 1994, Science.

[182]  A. Rundell,et al.  Gene therapy by intramuscular injection of plasmid DNA: studies on firefly luciferase gene expression in mice. , 1993, Human gene therapy.

[183]  R. Steinman,et al.  The dendritic cell system and its role in immunogenicity. , 1991, Annual review of immunology.

[184]  G. Trinchieri,et al.  Fc gamma R(CD16) interaction with ligand induces Ca2+ mobilization and phosphoinositide turnover in human natural killer cells. Role of Ca2+ in Fc gamma R(CD16)-induced transcription and expression of lymphokine genes , 1989, The Journal of experimental medicine.